Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Merck revealed promising Phase 3 trial results for WINREVAIR, a new treatment aimed at pulmonary arterial hypertension (PAH). The HYPERION study involved about 320 global participants already ...

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial.

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend use of ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...